Slumping HIVE Blockchain stock is still a buy, PI says

The Ethereum blockchain will soon undergo a significant upgrade but the development will have a neutral impact on HIVE Blockchain Technologies (HIVE Blockchain Stock Quote, Chart TSXV:HIVE), says analyst David Kwan of PI Financial. In a Friday update to clients, Kwan reiterated his “Buy” rating with the lowered price target of C$0.60 (previously C$0.70).

Blockchain platform Ethereum is about to get a system-wide upgrade called Constantinople, which is aimed at increasing transaction efficiency and will entail among other things changes to code execution and, important for HIVE’s purposes, a change in the blockchain reward system so that cryptominers will gain two Ether units per block instead of the three they currently receive.

Kwan says the overall impact on HIVE will be neutral.

“Other things being equal, this would negatively impact the economics of miners but we would expect that in the absence of a related increase in the price of Ether, we believe network hashrates and difficulty would decline, as mining activity would likely decrease as more miners would face unprofitable mining operations,” says Kwan.

The analyst says that HIVE is now able to operate a more diversified spectrum of mining operations due to its cloud ASIC mining now up and running, but he has lowered his forecasts, nonetheless, due to the continuing decline in cryptocurrency prices. He now assumes a Bitcoin price of $6,600 (was $6,900) and an Ether price of $230 (was $300). (All figures in US dollars unless noted otherwise.)

Kwan sees HIVE generating revenue and Adj. EBITDA in fiscal 2019 of $39.4 million and $6.3 million, respectively, and revenue and Adj. EBITDA in fiscal 2020 of $53.3 million and $13.8 million, respectively.

His C$0.70 target stems from a 12x his calendar 2019 Adjusted EBITDA estimate valuation and represents a 12-month projected return of 16.7 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: hive
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

2 days ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

2 days ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

2 days ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

3 days ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

3 days ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

3 days ago